|
SQSTM1
|
sequestosome 1 |
- NRIF signals cell death from the nucleus
- p75NTR recruits signalling complexes
- NF-kB is activated and signals survival
- PINK1-PRKN Mediated Mitophagy
- Neddylation
- Interleukin-1 signaling
- Pexophagy
- Signaling by ALK fusions and activated point mutants
- KEAP1-NFE2L2 pathway
- Nuclear events mediated by NFE2L2
|
|
- Paget's disease of bone and related disorders, including: ; Paget's disease of bone (PDB); Familial expansile osteolysis (FEO); Early-onset Paget's disease of bone (PDB2); Expansile skeletal hyperphosphatasia (ESH); Juvenile Paget's disease (JPD)
|
|
SRC
|
SRC proto-oncogene, non-receptor tyrosine kinase |
- Signaling by ERBB2
- Nuclear signaling by ERBB4
- Downregulation of ERBB4 signaling
- PIP3 activates AKT signaling
- GAB1 signalosome
- Downstream signal transduction
- Constitutive Signaling by Aberrant PI3K in Cancer
- Integrin signaling
- GRB2:SOS provides linkage to MAPK signaling for Integrins
- p130Cas linkage to MAPK signaling for integrins
- G alpha (s) signalling events
- G alpha (i) signalling events
- G alpha (i) signalling events
- DCC mediated attractive signaling
- DCC mediated attractive signaling
- Netrin mediated repulsion signals
- Regulation of commissural axon pathfinding by SLIT and ROBO
- RAF activation
- MAP2K and MAPK activation
- Signaling by moderate kinase activity BRAF mutants
- Signaling by high-kinase activity BRAF mutants
- Signaling by BRAF and RAF1 fusions
- Paradoxical activation of RAF signaling by kinase inactive BRAF
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- MET activates PTK2 signaling
- InlA-mediated entry of Listeria monocytogenes into host cells
- Regulation of RUNX1 Expression and Activity
- RUNX2 regulates osteoblast differentiation
- Regulation of RUNX3 expression and activity
- Extra-nuclear estrogen signaling
- RHOU GTPase cycle
- Activated NTRK2 signals through FYN
- Activated NTRK3 signals through PI3K
- Activated NTRK3 signals through PI3K
- Long-term potentiation
- GPER1 signaling
- Signaling downstream of RAS mutants
- Signaling by RAF1 mutants
- Signaling by CSF1 (M-CSF) in myeloid cells
- Degradation of CDH1
|
- Dasatinib
- RU84687
- RU79256
- N6-Benzyl Adenosine-5'-Diphosphate
- RU85493
- RU78262
- Phosphonotyrosine
- Malonic acid
- RU83876
- RU90395
- RU79072
- RU78783
- 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
- PASBN
- 2-[4-[(Z)-2-Acetamido-3-oxo-3-[[(3S)-2-oxo-1-[(4-phenylphenyl)methyl]azepan-3-yl]amino]prop-1-enyl]-2-formylphenyl]acetic acid
- PAS219
- DPI59
- RU82197
- Phenylphosphate
- RU78300
- RU79073
- RU82209
- ISO24
- RU85053
- RU78299
- Oxalic Acid
- RU78191
- Citric acid
- Paratoulene phosphate
- 4-[(4-METHYL-1-PIPERAZINYL)METHYL]-N-[3-[[4-(3-PYRIDINYL)-2-PYRIMIDINYL]AMINO]PHENYL]-BENZAMIDE
- Purvalanol A
- XL228
- Tirbanibulin
- Bosutinib
- 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea
- 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-phenylurea
- 3-[4-AMINO-1-(1-METHYLETHYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL]PHENOL
- PD-168393
- [4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl}amino)phenyl]acetonitrile
- PP-121
- 1-cyclobutyl-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
- 1-(1-methylethyl)-3-quinolin-6-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine
- 2-(4-CARCOXY-5-ISOPROPYLTHIAZOLYL)BENZOPIPERIDINE
- N-(4-PHENYLAMINO-QUINAZOLIN-6-YL)-ACRYLAMIDE
- (2E)-N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide
- Ponatinib
- Nintedanib
- Fostamatinib
|
|
|
STAMBP
|
STAM binding protein |
|
|
|
|
STK17A
|
serine/threonine kinase 17a |
|
|
|
|
STK26
|
serine/threonine kinase 26 |
- Apoptotic cleavage of cellular proteins
|
- 2-[4-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl]iminocyclohexa-2,5-dien-1-yl]acetonitrile
- Fostamatinib
|
|
|
STRADB
|
STE20 related adaptor beta |
- Energy dependent regulation of mTOR by LKB1-AMPK
|
|
|
|
STUB1
|
STIP1 homology and U-box containing protein 1 |
- Downregulation of TGF-beta receptor signaling
- RIPK1-mediated regulated necrosis
- Regulation of TNFR1 signaling
- Regulation of necroptotic cell death
- Downregulation of ERBB2 signaling
- Regulation of RUNX2 expression and activity
- Regulation of PTEN stability and activity
- Antigen processing: Ubiquitination & Proteasome degradation
|
|
|
|
SUFU
|
SUFU negative regulator of hedgehog signaling |
- Degradation of GLI1 by the proteasome
- Degradation of GLI1 by the proteasome
- Degradation of GLI2 by the proteasome
- GLI3 is processed to GLI3R by the proteasome
- Hedgehog 'off' state
- Hedgehog 'on' state
|
|
- Basal cell nevus syndrome; Nevoid basal cell carcinoma syndrome; Gorlin syndrome
|
|
SYK
|
spleen associated tyrosine kinase |
- GPVI-mediated activation cascade
- GPVI-mediated activation cascade
- FCGR activation
- FCGR activation
- Regulation of actin dynamics for phagocytic cup formation
- Role of phospholipids in phagocytosis
- DAP12 signaling
- Fc epsilon receptor (FCERI) signaling
- Fc epsilon receptor (FCERI) signaling
- Role of LAT2/NTAL/LAB on calcium mobilization
- Role of LAT2/NTAL/LAB on calcium mobilization
- FCERI mediated MAPK activation
- FCERI mediated Ca+2 mobilization
- FCERI mediated Ca+2 mobilization
- Integrin signaling
- CLEC7A (Dectin-1) signaling
- Dectin-2 family
- Dectin-2 family
- Interleukin-2 signaling
- Regulation of signaling by CBL
- Regulation of signaling by CBL
- FCGR3A-mediated IL10 synthesis
- FCGR3A-mediated phagocytosis
- Signaling by CSF3 (G-CSF)
- Signaling by CSF3 (G-CSF)
- Potential therapeutics for SARS
- Inactivation of CSF3 (G-CSF) signaling
- Inactivation of CSF3 (G-CSF) signaling
- FLT3 signaling through SRC family kinases
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
|
- Staurosporine
- N-(2-hydroxy-1,1-dimethylethyl)-1-methyl-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indole-5-carboxamide
- Tamatinib
- 2-{2-[(3,5-dimethylphenyl)amino]pyrimidin-4-yl}-N-[(1S)-2-hydroxy-1-methylethyl]-4-methyl-1,3-thiazole-5-carboxamide
- 2-{[(1R,2S)-2-aminocyclohexyl]amino}-4-[(3-methylphenyl)amino]pyrimidine-5-carboxamide
- Ellagic acid
- Fostamatinib
- Entospletinib
|
|
|
TAB1
|
TGF-beta activated kinase 1 (MAP3K7) binding protein 1 |
- NOD1/2 Signaling Pathway
- FCERI mediated NF-kB activation
- TAK1-dependent IKK and NF-kappa-B activation
- activated TAK1 mediates p38 MAPK activation
- JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1
- TNFR1-induced NF-kappa-B signaling pathway
- CLEC7A (Dectin-1) signaling
- Ub-specific processing proteases
- TICAM1,TRAF6-dependent induction of TAK1 complex
- Interleukin-1 signaling
- IRAK2 mediated activation of TAK1 complex
- TRAF6-mediated induction of TAK1 complex within TLR4 complex
- Alpha-protein kinase 1 signaling pathway
- SARS-CoV-2 activates/modulates innate and adaptive immune responses
- IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation
|
|
|
|
TAB2
|
TGF-beta activated kinase 1 (MAP3K7) binding protein 2 |
- Nuclear signaling by ERBB4
- Nuclear signaling by ERBB4
- NOD1/2 Signaling Pathway
- Downstream TCR signaling
- FCERI mediated NF-kB activation
- TAK1-dependent IKK and NF-kappa-B activation
- activated TAK1 mediates p38 MAPK activation
- JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1
- TNFR1-induced NF-kappa-B signaling pathway
- CLEC7A (Dectin-1) signaling
- TICAM1,TRAF6-dependent induction of TAK1 complex
- Interleukin-1 signaling
- IRAK2 mediated activation of TAK1 complex
- TRAF6-mediated induction of TAK1 complex within TLR4 complex
- Alpha-protein kinase 1 signaling pathway
- SARS-CoV-2 activates/modulates innate and adaptive immune responses
- IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation
|
|
|
|
TAB3
|
TGF-beta activated kinase 1 (MAP3K7) binding protein 3 |
- NOD1/2 Signaling Pathway
- FCERI mediated NF-kB activation
- TAK1-dependent IKK and NF-kappa-B activation
- activated TAK1 mediates p38 MAPK activation
- JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1
- TNFR1-induced NF-kappa-B signaling pathway
- CLEC7A (Dectin-1) signaling
- TICAM1,TRAF6-dependent induction of TAK1 complex
- Interleukin-1 signaling
- IRAK2 mediated activation of TAK1 complex
- TRAF6-mediated induction of TAK1 complex within TLR4 complex
- Alpha-protein kinase 1 signaling pathway
- SARS-CoV-2 activates/modulates innate and adaptive immune responses
- IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation
|
|
|
|
TANK
|
TRAF family member associated NFKB activator |
- TICAM1-dependent activation of IRF3/IRF7
- TRAF6 mediated IRF7 activation
- Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE)
- Regulation of TBK1, IKKε (IKBKE)-mediated activation of IRF3, IRF7
- Regulation of TBK1, IKKε-mediated activation of IRF3, IRF7 upon TLR3 ligation
|
|
|
|
TAX1BP1
|
Tax1 binding protein 1 |
- Regulation of TNFR1 signaling
- Negative regulators of DDX58/IFIH1 signaling
|
|
|
|
TDP2
|
tyrosyl-DNA phosphodiesterase 2 |
- Nonhomologous End-Joining (NHEJ)
|
|
|
|
TGFBR1
|
transforming growth factor beta receptor 1 |
- Downregulation of TGF-beta receptor signaling
- Downregulation of TGF-beta receptor signaling
- TGF-beta receptor signaling activates SMADs
- TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
- TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- TGFBR2 Kinase Domain Mutants in Cancer
- TGFBR1 KD Mutants in Cancer
- TGFBR1 LBD Mutants in Cancer
- UCH proteinases
- Ub-specific processing proteases
- TGFBR3 regulates TGF-beta signaling
|
- 4-(3-Pyridin-2-Yl-1h-Pyrazol-4-Yl)Quinoline
- Naphthyridine Inhibitor
- 3-(4-Fluorophenyl)-2-(6-Methylpyridin-2-Yl)-5,6-Dihydro-4h-Pyrrolo[1,2-B]Pyrazole
- N-[4-(5-fluoro-6-methylpyridin-2-yl)-5-quinoxalin-6-yl-1H-imidazol-2-yl]acetamide
- 2-(6-methylpyridin-2-yl)-N-pyridin-4-ylquinazolin-4-amine
- N-1H-indazol-5-yl-2-(6-methylpyridin-2-yl)quinazolin-4-amine
- Fostamatinib
|
- Loeys-Dietz syndrome (LDS)
- Familial thoracic aortic aneurysm and dissection (TAAD); Aortic aneurysm familial thoracic type (AAT)
|
|
TICAM1
|
TIR domain containing adaptor molecule 1 |
- Caspase activation via Death Receptors in the presence of ligand
- MyD88-independent TLR4 cascade
- Toll Like Receptor 3 (TLR3) Cascade
- TICAM1, RIP1-mediated IKK complex recruitment
- RIP-mediated NFkB activation via ZBP1
- TRIF-mediated programmed cell death
- TICAM1 deficiency - HSE
- TRAF3 deficiency - HSE
- TLR3-mediated TICAM1-dependent programmed cell death
- TICAM1-dependent activation of IRF3/IRF7
- TICAM1,TRAF6-dependent induction of TAK1 complex
- Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE)
- IKK complex recruitment mediated by RIP1
- TRAF6-mediated induction of TAK1 complex within TLR4 complex
- IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation
- Regulation of TBK1, IKKε (IKBKE)-mediated activation of IRF3, IRF7
- Regulation of TBK1, IKKε-mediated activation of IRF3, IRF7 upon TLR3 ligation
|
|
|
|
TICAM2
|
TIR domain containing adaptor molecule 2 |
- Caspase activation via Death Receptors in the presence of ligand
- Toll Like Receptor 4 (TLR4) Cascade
- MyD88-independent TLR4 cascade
- TRIF-mediated programmed cell death
- Neutrophil degranulation
- Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE)
- IKK complex recruitment mediated by RIP1
- TRAF6-mediated induction of TAK1 complex within TLR4 complex
- IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation
- Regulation of TBK1, IKKε (IKBKE)-mediated activation of IRF3, IRF7
|
|
|
|
TIFA
|
TRAF interacting protein with forkhead associated domain |
- TAK1-dependent IKK and NF-kappa-B activation
- Alpha-protein kinase 1 signaling pathway
|
|
|
|
TIRAP
|
TIR domain containing adaptor protein |
- ER-Phagosome pathway
- MyD88:MAL(TIRAP) cascade initiated on plasma membrane
- MyD88 deficiency (TLR2/4)
- IRAK4 deficiency (TLR2/4)
|
|
|